

CSD/BSE&NSE/EGM 2025
04th June, 2025

To
Listing Department
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Additional disclosure in the Notice of Extra-Ordinary General Meeting (EGM) of the Company

Ref: Requirement letter dated 04th June, 2025 issued by NSE referring to in-principle approval sought by the Company for the proposed preferential issue of warrants

With reference to above subject and pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the Company has informed through its earlier intimations that the Extra-Ordinary General Meeting (EGM) of the Company **will be held on Thursday, June 05, 2025 at 11:30 a.m. IST, through Video Conference (VC) / Other Audio Visual Means (OAVM).**

Pursuant to the Regulation 28(1) of the SEBI (LODR) Regulations, 2015, the Company had filed applications for obtaining in-principle approval of National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) in relation to proposed preferential issue of convertible warrants of the Company.

Further, pursuant to the requirement letter dated 4th June 2025 received from the NSE, our Company is providing the additional disclosure in accordance with the SEBI (ICDR) Regulation, 2018 with respect to UBO for one of the allottees at the point no. 10 as set forth in the explanatory statement relating to Item No. 2 of the EGM Notice as under:

Name of the Proposed Allottee	Pre-Issue Shareholding*		No. of warrants to be Issued/ allotted	Post-Issue Shareholding #		Ultimate Beneficial Owners of the Proposed Allottees
	No. of Equity Shares	% of share holding		No. of Equity Shares	% of share holding	
ABAKKUS DIVERSIFIED ALPHA FUND	Nil	-	29,85,000	29,85,000	1.06	Sunil Singhania

** as on 09th May, 2025*

assuming full conversion of warrants into equity shares

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Except information/details as provided in corrigendum dated 27th May, 2025 and this additional disclosure given, all other contents and disclosures of the Notice of EGM dated 13th May 2025 shall remain unchanged.

This additional disclosure letter will be hosted on the Company's website at:

<https://www.suven.com/egm.aspx>.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com